DDInter38 DDInter1631
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Interferon alfa-n1
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Aldesleukin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfa-n1